The Medipattern Corporation
TSX VENTURE : MKI

The Medipattern Corporation

November 07, 2005 06:30 ET

Medipattern Announces General Market Release of B-Cad'TM' 1.0

TORONTO, ONTARIO--(CCNMatthews - Nov. 7, 2005) -

Attention: Business/Financial Editors:

The Medipattern Corporation (TSX VENTURE:MKI), a leading developer of computer-aided detection (CAD) software applications for medical imaging, today announced the general market release of its innovative new software for breast ultrasound, B-CAD™ 1.0.

Highlights:

- Computer-Aided Detection (CAD) solution designed to assist radiologists in the analysis of breast ultrasound images;

- Powerful application for breast ultrasound analysis and training;

- Quick analysis and automated reporting of breast ultrasound images with this powerful application;

- Produces consistent breast ultrasound reports in compliance with the American College of Radiology (ACR) Breast-Imaging (BI-RADS®) Lexicon;

- Application to be marketed by Cedara Software as part of Cedara B-CAD 1.0.

B-CAD 1.0, designed to assist in the analysis and reporting of lesions in breast ultrasound, will be integrated into Cedara Software's newly launched Cedara B-CAD 1.0, along with Cedara Software's I-ReadMammo™ Breast Imaging Suite that enables easy access and retrieval of stored medical images for Breast Centers. Cedara's B-CAD 1.0 represents a strong shift for breast ultrasound image analysis and CAD applications in general and will help to break down the barriers to providing efficient clinical solutions for better patient care.

"B-CAD is one of the most innovative applications for breast ultrasound on the market," said Dr. Ellen Mendelson of Northwestern Memorial Hospital in Chicago, "At our institution, B-CAD will be an excellent teaching tool for newcomers to breast ultrasound. For trained radiologists, it will also have a positive impact, spreading acceptance of the ACR BI-RADS® lexicon for breast ultrasound and assisting in the classification of breast lesions."

Representing more than five years of development, B-CAD is the world's first commercially available CAD solution designed to assist radiologists in the analysis of breast lesions using ultrasound images. Uniquely positioned to reduce the time required by a radiologist to analyze and report the findings of breast ultrasound images, B-CAD provides tools for automatic image analysis, segmentation, and classification. To address hospital-wide needs for consistent reporting practices, B-CAD provides a standardized reporting structure, as defined by the ACR BI-RADS® Ultrasound Lexicon Classification Form.

"We are pleased at the response we have been receiving for B-CAD," said Jeff Collins, CEO of Medipattern. "B-CAD was designed specifically to be easily integrated into existing applications and workflows so that we can leverage the technology already in place at breast imaging facilities. We are confident that this integration with Cedara is just the first of many OEM partnerships and that end users will continue to see the advantages our system has to offer."

B-CAD is available through Cedara Software to OEM organizations interested in expanding their capabilities in breast imaging and through Merge Healthcare for end users.

Prior to general market release and integration into Cedara's I-ReadMammo, B-CAD had been beta tested with good response at several luminary sites across North America, including Northwestern Memorial Hospital in Chicago, University of British Columbia in Vancouver, B.C. and Weinstein Imaging Associates, Pittsburgh, Pennsylvania.

"CAD is increasingly become a standard of care in breast imaging," said Sabrina Cannistraro, Product Manager for Women's Health at Cedara Software. "CAD solutions for Mammography and MRI have quickly won credibility in clinical environments, and ultrasound marks a large, as yet undeveloped, market."

B-CAD was 510(k) cleared by the US FDA in May 2005. Cedara B-CAD and the latest Medipattern initiatives will be highlighted at RSNA in the Cedara and Merge booths later this month in Chicago.

The Medipattern Corporation develops computer-aided detection (CAD) software applications for medical imaging. Medipattern delivers medical imaging software that enhances workflow while improving interpretive and diagnostic confidence. The Company's initial clinical application is CAD for breast ultrasound (B-CAD™). B-CAD uses pattern recognition technology to assist radiologists in their efforts to classify and characterize lesions in ultrasound images of the breast. For additional information, please visit the company's website at: www.medipattern.com.

B-CAD™ is a trademark of The Medipattern Corporation.

Cedara B-CAD™ is a trademark of Cedara Software Corp.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's financial performance, operations or to the environment in which it operates, which are based on Medipattern's operations, estimates, forecasts, and projections. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict, or are beyond the company's control. A number of important factors could cause actual outcomes and results to differ materially from those expressed in these forward-looking statements. These factors include those set forth in the company's corporate filings, (posted at www.sedar.com). Consequently, readers should not rely on such forward-looking statements. In addition, these forward-looking statements relate to the date on which they are made. Although the forward-looking statements contained herein are based upon what management believes to be reasonable assumptions, Medipattern cannot be certain that actual results will be consistent with these forward-looking statements, and the company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

The TSX Venture Exchange has in no way passed on the merits of the transaction described herein.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved of the contents of this release.

Contact Information